Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TapImmune Inc (OTCQB:TPIV)

Delayed Data
As of Feb 05
 -0.0038 / -0.63%
Today’s Change
Today|||52-Week Range
Consumer Services
Other Consumer Services

Company Description

TapImmune, Inc. is focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company combines a set of proprietary technologies to improve the ability of the cellular immune system to destroy diseased cells. It also provides treatment for other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system. TapImmune was founded in 1991 and is headquartered in Seattle, Washington.

Contact Information

TapImmune, Inc.
1551 Eastlake Avenue East
Seattle Washington 98102
P:(206) 504-7280
Investor Relations:
(206) 504-7267



Individual stakeholders9.49%
Mutual fund holders--
Other institutional--

Top Executives

Glynn WilsonChairman, CEO, CFO, Secretary & CAO
Robert Z. FlorkiewiczSenior Director-Molecular Biology & Head-Research
Mark ReddishDirector & Vice President-Development